What is the role of lofexidine (Lucemyra) in the treatment of opioid withdrawal?

Updated: Jun 21, 2018
  • Author: David W Dixon, DO; Chief Editor: Glen L Xiong, MD  more...
  • Print

Lofexidine (Lucemyra) is an oral centrally-acting alpha2 agonist approved by the FDA in May 2018 for mitigation of opioid withdrawal symptoms in adults. Approval was supported by 2 randomized, double-blind, placebo-controlled clinical trials, an open-label study, and clinical pharmacology studies with concomitant administration of either methadone, buprenorphine, or naltrexone. Data show that compared to placebo, participants treated with lofexidine experienced less severe withdrawal symptoms and were significantly more likely to complete a 7-day opioid discontinuation treatment. [84, 85]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!